Nevis Brands（NEVI）株式概要ネビス・ブランズ社は米国で大麻製品の開発・販売を行っている。 詳細NEVI ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より86.9%で取引されている 過去5年間の収益は年間31%増加しました。 リスク分析Canadian市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( CA$1M )意味のある収益がありません ( CA$2M )すべてのリスクチェックを見るNEVI Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$0.0396.1% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-3m23m2016201920222025202620282031Revenue CA$23.4mEarnings CA$2.3mAdvancedSet Fair ValueView all narrativesNevis Brands Inc. 競合他社NeutriSci InternationalSymbol: TSXV:NU.HMarket cap: CA$892.1kPsyched WellnessSymbol: CNSX:PSYCMarket cap: CA$4.1mIrwin NaturalsSymbol: CNSX:IWINMarket cap: CA$1.0mVitality ProductsSymbol: TSXV:VPIMarket cap: CA$828.2k価格と性能株価の高値、安値、推移の概要Nevis Brands過去の株価現在の株価US$0.0352週高値US$0.09552週安値US$0.025ベータ0.831ヶ月の変化0%3ヶ月変化-40.00%1年変化-40.00%3年間の変化n/a5年間の変化-94.55%IPOからの変化-97.39%最新ニュースNew Risk • Apr 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Market cap is less than US$10m (CA$1.36m market cap, or US$991.6k). Minor Risk Revenue is less than US$5m (CA$1.7m revenue, or US$1.2m).Reported Earnings • Mar 19Full year 2025 earnings released: CA$0.007 loss per share (vs CA$0.009 loss in FY 2024)Full year 2025 results: CA$0.007 loss per share (improved from CA$0.009 loss in FY 2024). Revenue: CA$1.70m (up 9.4% from FY 2024). Net loss: CA$275.1k (loss narrowed 24% from FY 2024).Reported Earnings • Oct 23Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.001 profit in 3Q 2024)Third quarter 2025 results: CA$0.001 loss per share (down from CA$0.001 profit in 3Q 2024). Revenue: CA$478.8k (flat on 3Q 2024). Net loss: CA$33.7k (down 221% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 16Second quarter 2025 earnings released: EPS: CA$0 (vs CA$0.002 loss in 2Q 2024)Second quarter 2025 results: EPS: CA$0 (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$418.7k (down 4.1% from 2Q 2024). Net loss: CA$11.5k (loss narrowed 82% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • Jun 30Nevis Brands Inc., Annual General Meeting, Aug 27, 2025Nevis Brands Inc., Annual General Meeting, Aug 27, 2025. Location: british columbia, vancouver Canadaお知らせ • Feb 21Nevis Brands Inc. announced that it expects to receive $0.1 million in fundingNevis Brands Inc. announced that it will issue an unsecured promissory note with returning investor, John Kueber for principal amount of $100,000 on February 20, 2025. The Kueber Note carry a coupon of 10% per annum and will mature on February 15, 2026. The transaction has been approved by the shareholder board.最新情報をもっと見るRecent updatesNew Risk • Apr 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Market cap is less than US$10m (CA$1.36m market cap, or US$991.6k). Minor Risk Revenue is less than US$5m (CA$1.7m revenue, or US$1.2m).Reported Earnings • Mar 19Full year 2025 earnings released: CA$0.007 loss per share (vs CA$0.009 loss in FY 2024)Full year 2025 results: CA$0.007 loss per share (improved from CA$0.009 loss in FY 2024). Revenue: CA$1.70m (up 9.4% from FY 2024). Net loss: CA$275.1k (loss narrowed 24% from FY 2024).Reported Earnings • Oct 23Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.001 profit in 3Q 2024)Third quarter 2025 results: CA$0.001 loss per share (down from CA$0.001 profit in 3Q 2024). Revenue: CA$478.8k (flat on 3Q 2024). Net loss: CA$33.7k (down 221% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Reported Earnings • Jul 16Second quarter 2025 earnings released: EPS: CA$0 (vs CA$0.002 loss in 2Q 2024)Second quarter 2025 results: EPS: CA$0 (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$418.7k (down 4.1% from 2Q 2024). Net loss: CA$11.5k (loss narrowed 82% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • Jun 30Nevis Brands Inc., Annual General Meeting, Aug 27, 2025Nevis Brands Inc., Annual General Meeting, Aug 27, 2025. Location: british columbia, vancouver Canadaお知らせ • Feb 21Nevis Brands Inc. announced that it expects to receive $0.1 million in fundingNevis Brands Inc. announced that it will issue an unsecured promissory note with returning investor, John Kueber for principal amount of $100,000 on February 20, 2025. The Kueber Note carry a coupon of 10% per annum and will mature on February 15, 2026. The transaction has been approved by the shareholder board.お知らせ • Oct 27Nevis Brands Inc. announced that it expects to receive $0.225 million in fundingNevis Brands Inc. announced a non-brokered private placement of up to 2,500,000 common shares at a price of $0.09 per share for aggregate gross proceeds of up to $225,000 on October 25, 2024. The transaction will include participation from certain insiders of the company. All securities issued in connection with the offering will be subject to a statutory hold period of four months and one day from the date of issuance.お知らせ • Jul 04Nevis Brands Inc., Annual General Meeting, Aug 29, 2024Nevis Brands Inc., Annual General Meeting, Aug 29, 2024. Location: british columbia, vancouver Canadaお知らせ • May 10Nevis Brands Inc Receives Necessary State Regulatory Approvals and Is Completing Production on 3 New Products to Add to Its Existing Portfolio of Products for Sale in Washington StateNevis Brands Inc. announced it has received necessary state regulatory approvals and is completing production on 3 new products to add to its existing portfolio of products for sale in Washington State. These include Major(TM) Apple Peach 100mg Shots Major(TM) Zero Cal Lemonade 100mg Shots Happy Apple (TM) 10mg Cans. These new products will be in market in May 2024 and are expected to contribute to the company's royalty revenues beginning June 2024. Washington State dispensaries currently sell over $700,000 per month of Nevis related products through licensed dispensaries. Products include Major(TM) in 9 flavors, Happy Apple(TM) 100mg bottles, Vertus(TM) a sparkling cider designed to emulate Prosecco, and Velvet Swing(TM). Nevis collects royalties on the sale of these products through its exclusive licensee in each market. The Company may also introduce these new products to licensees in other states. Nevis Brands products are currently sold in Washington, Oregon, Arizona, Ohio, Colorado, California, Missouri and Nevada. The Company is preparing for production in Michigan.お知らせ • Dec 19Nevis Brands Inc. Announces Product Extension in OhioNevis Brands Inc. announced several corporate updates: Product Extension in Ohio: The Company has expanded its Major line of beverages to include a 6th flavor of Major: Atomic Apple. Production has now been completed and inventory is being sold to Ohio retailers. Product Expansion: Washington State. The Company has filed 3 new products for approval in Washington State. The products include two new beverage products and an additional edible product. Nevis will announce specifics of the products upon approval and when production has started.お知らせ • May 19Pascal Biosciences Inc.'s Shares Will Be De-Listed from the TSX.V At the Close of the Market on May 23, 2023Shareholders of Pascal Biosciences Inc. owning 56% of the issued shares of the company have approved the reorganization of the company, including delisting from the TSX Venture Exchange. Details of the reorganization were disclosed in prior releases dated Dec. 9, 2022, and Feb. 15, 2023. At the request of the Company, the Shares will be de-listed from the TSX.V at the close of the market on May 23, 2023. Immediately thereafter: (i) the Company's name will be changed to Nevis Brands Inc., (ii) the Shares will consolidate on the basis of one new share for five old shares, and (iii) the Company's board of directors and the CEO will change. A news release will be issued the next day providing details about the new directors and the CEO. The Company has received a conditional listing letter dated April 26, 2023 from the Canadian Securities Exchange (the "CSE"). That letter requires the Company's reorganization to complete on the day the Shares are listed on the CSE (the "Listing Date"). On the Listing Date, a private placement of $2,000,000 (the "Private Placement") and the acquisition of THC Essentials (the Acquisition") are required to close as well as issuing Shares for debt, which will complete the reorganization. Completion of the transactions disclosed in this press release are subject to a number of conditions, including closing the Private Placement and the Acquisition. There can be no assurance that the Transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in further news releases or the CSE form 2AListing Statement, still to be finalized, any information released or received with respect to the transactions may not be accurate or complete and should not be relied upon. The Shares of the Company have been halted since the first week of December 2022.Board Change • Apr 27High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 4 experienced directors. No highly experienced directors. Independent Director Terry Pearson is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 22Pascal Biosciences Inc. To File Patent For COVID-19 Antiviral Activity With CBDPascal Biosciences Inc. was the first to report cannabinoids can kill SARS-CoV-2, the virus that causes Covid-19. Pascal filed an international patent covering this work prior to the press release in July 2020, and now it is clear that Pascal was the first to file to protect this discovery. This means that Pascal holds the rights to therapeutic treatment of Covid-19 by cannabinoids, particularly CBD. Pascal scientists have replicated this work in four different antiviral assays and have also shown that CBD has an antiviral activity similar to remdesivir, a Gilead Sciences drug approved for treatment of Covid-19. Furthermore, Pascal's discovery has been confirmed and extended by several academic groups. A lab at the University of Chicago has recently shown that CBD suppressed infection in mice, and also that epilepsy patients treated with CBD have significantly lower rates of SARS-CoV-2 infection than matched patients. A separate academic study suggests that CBD viral blockade is not variant specific, so CBD treatment should be beneficial as the virus mutates during the pandemic. There are currently at least four clinical trials testing CBD in Covid-19 patients. While Pascal is not involved in those studies, the rights to treat patients would be covered by Pascal's patent if CBD is approved by regulatory officials. After 18 months, patent submissions become public information. The absence of other patents predating Pascal's submission date confirm that Pascal was the first to file and protect this discovery.お知らせ • Mar 03+ 1 more updatePascal Biosciences Inc. Announces Change of CEOPascal Biosciences Inc. announced the appointment of Dr. Brian Bapty as Chief Executive Officer, for a five year term which can be renewed. He has served as an independent strategic advisor to the industry, Director of Business Development at Helius Medical Technologies and CEO and Healthcare Investment Banker in a boutique brokerage firm. Dr. Bapty takes over from the previous CEO Robert Gietl. On January 3, 2022, Mr. Gietl was terminated as CEO and president.お知らせ • Jun 09Pascal Biosciences Inc. Receives Grant of USD 343,750 from National Cancer Institute of the US National Institutes of Health for Leukemia ProgramPascal Biosciences Inc. announced that it has been awarded a grant of USD 343,750 from the National Cancer Institute of the US National Institutes of Health. This two-year award will fund development of the company’s antibody drug for Acute Lymphoblastic Leukemia (ALL), which is the most common childhood leukemia. The company is the first to advance an antibody targeting the highly leukemia-specific protein, VpreB, for treating ALL. The company’s drug will be eligible for orphan drug designation, which can enable financial incentives and a seven year marketing exclusivity. The company has filed for patent protection for its ALL treatment. While the number of patients with ALL is relatively small, the market potential for the company’s drug could be significant.Executive Departure • May 01CFO & Corporate Secretary has left the companyOn the 30th of April, Judith Dalling's tenure as CFO & Corporate Secretary ended after 7.9 years in the role. We don't have any record of a personal shareholding under Judith's name. A total of 3 executives have left over the last 12 months.お知らせ • Mar 18Pascal Biosciences Inc. announced that it has received CAD 0.75 million in fundingOn March 17, 2021, Pascal Biosciences Inc. (TSXV:PAS) closed the transaction. The company issued 1,900,000 units for gross proceeds of CAD 190,000 in its second tranche. The company paid a finders fees of CAD 1,365 in the second trache. Certain directors and officers of the Company acquired 1,255,000 Units under the Private Placement. The transaction is subject to final acceptance by the TSX Venture Exchange upon filing of final documents.お知らせ • Nov 03Pascal Biosciences Inc. announced that it expects to receive CAD 1 million in fundingPascal Biosciences Inc. (TSXV:PAS) announced a non-brokered private placement of up to 5,000,000 units at a price of CAD 0.20 per unit for gross proceeds of CAD 1,000,000 on November 2, 2020. The transaction may involve participation from certain directors and officers. Each unit will consist of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at a price of CAD 0.35 per share for a period of 12 months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the company may exercise once the units are free of resale restrictions and if the company’s shares are trading at or above a volume weighted average price of CAD 0.50 for 10 consecutive trading days, the warrants will expire upon 30 days from the date the company provides notice in writing to the warrant holders. The securities to be issued under the transaction will be subject to a four-month hold period and subject to the acceptance of the TSX Venture Exchange.お知らせ • Sep 29SORSE Technology entered into a non-binding term sheet to acquire Pascal Biosciences US, Inc. from Pascal Biosciences Inc. (TSXV:PAS) for $9.5 million.SORSE Technology entered into a non-binding term sheet to acquire Pascal Biosciences US, Inc. from Pascal Biosciences Inc. (TSXV:PAS) for $9.5 million on March 10, 2020. Under the transaction, SORSE Technology will issue its shares as consideration for the acquisition. As additional consideration for the sale, SORSE Technology will permit Pascal Biosciences US, Inc.'s employees to support Pascal's retained intellectual property and scientific programs at no additional cost to Pascal Biosciences Inc., in accordance with a work program to be determined in the definitive agreement. Upon closing of the transaction, Pascal Biosciences Inc. will hold at least 15.8% of the outstanding shares of SORSE Technology. Upon closing of the transaction, SORSE Technology will invest an additional $0.25 million in Pascal Biosciences Inc. on a private placement basis. Pursuant to the term sheet, Pascal Biosciences Inc. has agreed to exclusively negotiate the terms of the transaction with SORSE Technology until May 27, 2020. If entered into, the definitive agreement, and any ancillary transaction agreements, will contain representations and warranties, conditions relating to regulatory approvals, TSX Venture Exchange approvals and any required shareholder approvals, and other terms as are customary in comparable transactions of this nature. In addition, if transaction results in the sale of more than 50% of Pascal Biosciences Inc.’s assets, business or undertaking, as an additional condition to closing of the transaction, Pascal Biosciences Inc. will be required to obtain approval from its shareholders in accordance with Policy 5.3 of the TSX Venture Exchange.お知らせ • Sep 26Pascal Biosciences Inc. Confirms an Earlier Report Certain Cannabinoids Block Replication of SARS-CoV-2Pascal Biosciences Inc. announced the Company has confirmed an earlier report that certain cannabinoids block replication of SARS-CoV-2, the coronavirus that causes COVID-19. Four different laboratories have now experimentally verified the antiviral activity of a cannabinoid. In addition, several cannabinoids have been tested, and the optimal compound has been chosen for further study. The best cannabinoid had potency similar to remdesivir in two different assays. Remdesivir is an approved drug from Gilead that improves recovery time for COVID-19 patients. The four laboratories testing Pascal compounds are Southern Research, Institut Pasteur Korea, and two independent University of Washington academic groups. Three of the laboratories used the African green monkey kidney epithelial cell line, Vero E6, a common model system for testing coronaviral infectivity. In all three of these assays, the lead cannabinoid had good potency (antiviral activity in the range of 1 to 10 micromolar, similar to remdesivir). The fourth laboratory measured the antiviral effect on SARS-CoV- 2 on the human lung cell line, Calu-3, and found the cannabinoid to be nearly 100-fold more potent in inhibiting virus-mediated cell death than it was in the Vero E6 experiments. This is an important observation, as the human respiratory tract represents the first point of contact with the virus. Pascal scientists are very encouraged by the reproducibility of the cannabinoid's protective activity in different experimental systems and in different laboratories. These results support rationale for testing in animal models of COVID-19, both in single agent and in combination with other antiviral compounds such as remdesivir, and Pascal is currently planning these experiments. There are many efforts to create a vaccine or therapeutic drug for SARS-CoV-2 infection. Pascal's cannabinoid has the potential to limit the severity and progression of the disease. Typically, multiple drugs are required to provide effective antiviral therapy. For example, other viral diseases such as HIV and Hepatitis C require two or three drugs for effective treatment. The novel discovery by Pascal scientists suggests a cannabinoid may well become an essential component of an effective drug cocktail for the treatment of COVID-19. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.お知らせ • Sep 16Pascal Biosciences Inc. and SoRSE Technology Corporation Enters into a Collaborative Research Agreement to Advance Pascal’s PAS-393 into Clinical TestingPascal Biosciences Inc. and SoRSE Technology Corporation have entered into a Collaborative Research Agreement to advance Pascal’s PAS-393 into clinical testing. Pascal and SoRSE will share their respective technologies to test the cannabinoid PAS-393 in human volunteers, enabling testing of cancer patients treated with checkpoint inhibitors. As initially announced last March, this partnership leverages SoRSE’s formulation technology with Pascal’s proprietary cannabinoid programs for clinical trials. This will be the first pharmaceutical use of the novel formulation technology developed by SoRSE. The agreement will include Pascal’s intellectual property, which covers the use of cannabinoids in cancer patients treated with checkpoint inhibitors. SoRSE currently sells and licenses a proprietary water-soluble cannabinoid emulsion technology (patent-pending) that enables increased bioavailability, accurate dosing, and more than 12 months’ shelf stability. Pascal and SoRSE scientists will optimize a cannabinoid formulation for human subjects and will then test the formulated PAS-393 in volunteers. SoRSE will provide $750,000 in research funding to Pascal throughout the 15-month collaboration and will pay for related research expenditures. Following characterization of safety and pharmacology in a Phase 1a clinical trial, Pascal and SoRSE may elect to continue clinical development as equal partners in a Phase 1b cancer trial in combination with a checkpoint inhibitor. Dr. Gray will present scientific data this September 15th at the 3rd Annual International Cannabinoid-Derived Pharmaceutical Conference occurring in Boston, MA; the topic of his presentation is “Identifying and Validating Mechanism of Action In vivo/vitro.” SoRSE intends to collaborate with other researchers and product developers to study cannabinoids in other medical applications. Pascal will continue to pursue other non-cancer indications for PAS-393.株主還元NEVICA Personal ProductsCA 市場7D0%2.0%1.5%1Y-40.0%1.6%33.7%株主還元を見る業界別リターン: NEVI過去 1 年間で1.6 % の収益を上げたCanadian Personal Products業界を下回りました。リターン対市場: NEVIは、過去 1 年間で33.7 % のリターンを上げたCanadian市場を下回りました。価格変動Is NEVI's price volatile compared to industry and market?NEVI volatilityNEVI Average Weekly Movement19.3%Personal Products Industry Average Movement7.6%Market Average Movement10.2%10% most volatile stocks in CA Market18.0%10% least volatile stocks in CA Market3.9%安定した株価: NEVIの株価は、 Canadian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: NEVIの weekly volatility ( 19% ) は過去 1 年間安定していますが、依然としてCanadianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a2John Kueberwww.nevisbrands.comNevis Brands Inc.は米国で大麻製品の開発・販売を行っている。同社は麻由来のTHC飲料をMajorのブランド名で提供している。以前はパスカル・バイオサイエンシズ社として知られていたが、2023年6月にネビス・ブランズ社に社名変更。本社はワシントン州シアトル。もっと見るNevis Brands Inc. 基礎のまとめNevis Brands の収益と売上を時価総額と比較するとどうか。NEVI 基礎統計学時価総額CA$1.16m収益（TTM）-CA$275.07k売上高(TTM)CA$1.70m0.7xP/Sレシオ-4.2xPER（株価収益率NEVI は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計NEVI 損益計算書（TTM）収益CA$1.70m売上原価CA$657.81k売上総利益CA$1.04mその他の費用CA$1.31m収益-CA$275.07k直近の収益報告Nov 30, 2025次回決算日該当なし一株当たり利益（EPS）-0.0069グロス・マージン61.21%純利益率-16.22%有利子負債／自己資本比率47.8%NEVI の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/23 16:22終値2026/05/20 00:00収益2025/11/30年間収益2025/11/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Nevis Brands Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Apr 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Market cap is less than US$10m (CA$1.36m market cap, or US$991.6k). Minor Risk Revenue is less than US$5m (CA$1.7m revenue, or US$1.2m).
Reported Earnings • Mar 19Full year 2025 earnings released: CA$0.007 loss per share (vs CA$0.009 loss in FY 2024)Full year 2025 results: CA$0.007 loss per share (improved from CA$0.009 loss in FY 2024). Revenue: CA$1.70m (up 9.4% from FY 2024). Net loss: CA$275.1k (loss narrowed 24% from FY 2024).
Reported Earnings • Oct 23Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.001 profit in 3Q 2024)Third quarter 2025 results: CA$0.001 loss per share (down from CA$0.001 profit in 3Q 2024). Revenue: CA$478.8k (flat on 3Q 2024). Net loss: CA$33.7k (down 221% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 16Second quarter 2025 earnings released: EPS: CA$0 (vs CA$0.002 loss in 2Q 2024)Second quarter 2025 results: EPS: CA$0 (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$418.7k (down 4.1% from 2Q 2024). Net loss: CA$11.5k (loss narrowed 82% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • Jun 30Nevis Brands Inc., Annual General Meeting, Aug 27, 2025Nevis Brands Inc., Annual General Meeting, Aug 27, 2025. Location: british columbia, vancouver Canada
お知らせ • Feb 21Nevis Brands Inc. announced that it expects to receive $0.1 million in fundingNevis Brands Inc. announced that it will issue an unsecured promissory note with returning investor, John Kueber for principal amount of $100,000 on February 20, 2025. The Kueber Note carry a coupon of 10% per annum and will mature on February 15, 2026. The transaction has been approved by the shareholder board.
New Risk • Apr 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Market cap is less than US$10m (CA$1.36m market cap, or US$991.6k). Minor Risk Revenue is less than US$5m (CA$1.7m revenue, or US$1.2m).
Reported Earnings • Mar 19Full year 2025 earnings released: CA$0.007 loss per share (vs CA$0.009 loss in FY 2024)Full year 2025 results: CA$0.007 loss per share (improved from CA$0.009 loss in FY 2024). Revenue: CA$1.70m (up 9.4% from FY 2024). Net loss: CA$275.1k (loss narrowed 24% from FY 2024).
Reported Earnings • Oct 23Third quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.001 profit in 3Q 2024)Third quarter 2025 results: CA$0.001 loss per share (down from CA$0.001 profit in 3Q 2024). Revenue: CA$478.8k (flat on 3Q 2024). Net loss: CA$33.7k (down 221% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Reported Earnings • Jul 16Second quarter 2025 earnings released: EPS: CA$0 (vs CA$0.002 loss in 2Q 2024)Second quarter 2025 results: EPS: CA$0 (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$418.7k (down 4.1% from 2Q 2024). Net loss: CA$11.5k (loss narrowed 82% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • Jun 30Nevis Brands Inc., Annual General Meeting, Aug 27, 2025Nevis Brands Inc., Annual General Meeting, Aug 27, 2025. Location: british columbia, vancouver Canada
お知らせ • Feb 21Nevis Brands Inc. announced that it expects to receive $0.1 million in fundingNevis Brands Inc. announced that it will issue an unsecured promissory note with returning investor, John Kueber for principal amount of $100,000 on February 20, 2025. The Kueber Note carry a coupon of 10% per annum and will mature on February 15, 2026. The transaction has been approved by the shareholder board.
お知らせ • Oct 27Nevis Brands Inc. announced that it expects to receive $0.225 million in fundingNevis Brands Inc. announced a non-brokered private placement of up to 2,500,000 common shares at a price of $0.09 per share for aggregate gross proceeds of up to $225,000 on October 25, 2024. The transaction will include participation from certain insiders of the company. All securities issued in connection with the offering will be subject to a statutory hold period of four months and one day from the date of issuance.
お知らせ • Jul 04Nevis Brands Inc., Annual General Meeting, Aug 29, 2024Nevis Brands Inc., Annual General Meeting, Aug 29, 2024. Location: british columbia, vancouver Canada
お知らせ • May 10Nevis Brands Inc Receives Necessary State Regulatory Approvals and Is Completing Production on 3 New Products to Add to Its Existing Portfolio of Products for Sale in Washington StateNevis Brands Inc. announced it has received necessary state regulatory approvals and is completing production on 3 new products to add to its existing portfolio of products for sale in Washington State. These include Major(TM) Apple Peach 100mg Shots Major(TM) Zero Cal Lemonade 100mg Shots Happy Apple (TM) 10mg Cans. These new products will be in market in May 2024 and are expected to contribute to the company's royalty revenues beginning June 2024. Washington State dispensaries currently sell over $700,000 per month of Nevis related products through licensed dispensaries. Products include Major(TM) in 9 flavors, Happy Apple(TM) 100mg bottles, Vertus(TM) a sparkling cider designed to emulate Prosecco, and Velvet Swing(TM). Nevis collects royalties on the sale of these products through its exclusive licensee in each market. The Company may also introduce these new products to licensees in other states. Nevis Brands products are currently sold in Washington, Oregon, Arizona, Ohio, Colorado, California, Missouri and Nevada. The Company is preparing for production in Michigan.
お知らせ • Dec 19Nevis Brands Inc. Announces Product Extension in OhioNevis Brands Inc. announced several corporate updates: Product Extension in Ohio: The Company has expanded its Major line of beverages to include a 6th flavor of Major: Atomic Apple. Production has now been completed and inventory is being sold to Ohio retailers. Product Expansion: Washington State. The Company has filed 3 new products for approval in Washington State. The products include two new beverage products and an additional edible product. Nevis will announce specifics of the products upon approval and when production has started.
お知らせ • May 19Pascal Biosciences Inc.'s Shares Will Be De-Listed from the TSX.V At the Close of the Market on May 23, 2023Shareholders of Pascal Biosciences Inc. owning 56% of the issued shares of the company have approved the reorganization of the company, including delisting from the TSX Venture Exchange. Details of the reorganization were disclosed in prior releases dated Dec. 9, 2022, and Feb. 15, 2023. At the request of the Company, the Shares will be de-listed from the TSX.V at the close of the market on May 23, 2023. Immediately thereafter: (i) the Company's name will be changed to Nevis Brands Inc., (ii) the Shares will consolidate on the basis of one new share for five old shares, and (iii) the Company's board of directors and the CEO will change. A news release will be issued the next day providing details about the new directors and the CEO. The Company has received a conditional listing letter dated April 26, 2023 from the Canadian Securities Exchange (the "CSE"). That letter requires the Company's reorganization to complete on the day the Shares are listed on the CSE (the "Listing Date"). On the Listing Date, a private placement of $2,000,000 (the "Private Placement") and the acquisition of THC Essentials (the Acquisition") are required to close as well as issuing Shares for debt, which will complete the reorganization. Completion of the transactions disclosed in this press release are subject to a number of conditions, including closing the Private Placement and the Acquisition. There can be no assurance that the Transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in further news releases or the CSE form 2AListing Statement, still to be finalized, any information released or received with respect to the transactions may not be accurate or complete and should not be relied upon. The Shares of the Company have been halted since the first week of December 2022.
Board Change • Apr 27High number of new and inexperienced directorsThere are 7 new directors who have joined the board in the last 3 years. The company's board is composed of: 7 new directors. 4 experienced directors. No highly experienced directors. Independent Director Terry Pearson is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 22Pascal Biosciences Inc. To File Patent For COVID-19 Antiviral Activity With CBDPascal Biosciences Inc. was the first to report cannabinoids can kill SARS-CoV-2, the virus that causes Covid-19. Pascal filed an international patent covering this work prior to the press release in July 2020, and now it is clear that Pascal was the first to file to protect this discovery. This means that Pascal holds the rights to therapeutic treatment of Covid-19 by cannabinoids, particularly CBD. Pascal scientists have replicated this work in four different antiviral assays and have also shown that CBD has an antiviral activity similar to remdesivir, a Gilead Sciences drug approved for treatment of Covid-19. Furthermore, Pascal's discovery has been confirmed and extended by several academic groups. A lab at the University of Chicago has recently shown that CBD suppressed infection in mice, and also that epilepsy patients treated with CBD have significantly lower rates of SARS-CoV-2 infection than matched patients. A separate academic study suggests that CBD viral blockade is not variant specific, so CBD treatment should be beneficial as the virus mutates during the pandemic. There are currently at least four clinical trials testing CBD in Covid-19 patients. While Pascal is not involved in those studies, the rights to treat patients would be covered by Pascal's patent if CBD is approved by regulatory officials. After 18 months, patent submissions become public information. The absence of other patents predating Pascal's submission date confirm that Pascal was the first to file and protect this discovery.
お知らせ • Mar 03+ 1 more updatePascal Biosciences Inc. Announces Change of CEOPascal Biosciences Inc. announced the appointment of Dr. Brian Bapty as Chief Executive Officer, for a five year term which can be renewed. He has served as an independent strategic advisor to the industry, Director of Business Development at Helius Medical Technologies and CEO and Healthcare Investment Banker in a boutique brokerage firm. Dr. Bapty takes over from the previous CEO Robert Gietl. On January 3, 2022, Mr. Gietl was terminated as CEO and president.
お知らせ • Jun 09Pascal Biosciences Inc. Receives Grant of USD 343,750 from National Cancer Institute of the US National Institutes of Health for Leukemia ProgramPascal Biosciences Inc. announced that it has been awarded a grant of USD 343,750 from the National Cancer Institute of the US National Institutes of Health. This two-year award will fund development of the company’s antibody drug for Acute Lymphoblastic Leukemia (ALL), which is the most common childhood leukemia. The company is the first to advance an antibody targeting the highly leukemia-specific protein, VpreB, for treating ALL. The company’s drug will be eligible for orphan drug designation, which can enable financial incentives and a seven year marketing exclusivity. The company has filed for patent protection for its ALL treatment. While the number of patients with ALL is relatively small, the market potential for the company’s drug could be significant.
Executive Departure • May 01CFO & Corporate Secretary has left the companyOn the 30th of April, Judith Dalling's tenure as CFO & Corporate Secretary ended after 7.9 years in the role. We don't have any record of a personal shareholding under Judith's name. A total of 3 executives have left over the last 12 months.
お知らせ • Mar 18Pascal Biosciences Inc. announced that it has received CAD 0.75 million in fundingOn March 17, 2021, Pascal Biosciences Inc. (TSXV:PAS) closed the transaction. The company issued 1,900,000 units for gross proceeds of CAD 190,000 in its second tranche. The company paid a finders fees of CAD 1,365 in the second trache. Certain directors and officers of the Company acquired 1,255,000 Units under the Private Placement. The transaction is subject to final acceptance by the TSX Venture Exchange upon filing of final documents.
お知らせ • Nov 03Pascal Biosciences Inc. announced that it expects to receive CAD 1 million in fundingPascal Biosciences Inc. (TSXV:PAS) announced a non-brokered private placement of up to 5,000,000 units at a price of CAD 0.20 per unit for gross proceeds of CAD 1,000,000 on November 2, 2020. The transaction may involve participation from certain directors and officers. Each unit will consist of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at a price of CAD 0.35 per share for a period of 12 months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the company may exercise once the units are free of resale restrictions and if the company’s shares are trading at or above a volume weighted average price of CAD 0.50 for 10 consecutive trading days, the warrants will expire upon 30 days from the date the company provides notice in writing to the warrant holders. The securities to be issued under the transaction will be subject to a four-month hold period and subject to the acceptance of the TSX Venture Exchange.
お知らせ • Sep 29SORSE Technology entered into a non-binding term sheet to acquire Pascal Biosciences US, Inc. from Pascal Biosciences Inc. (TSXV:PAS) for $9.5 million.SORSE Technology entered into a non-binding term sheet to acquire Pascal Biosciences US, Inc. from Pascal Biosciences Inc. (TSXV:PAS) for $9.5 million on March 10, 2020. Under the transaction, SORSE Technology will issue its shares as consideration for the acquisition. As additional consideration for the sale, SORSE Technology will permit Pascal Biosciences US, Inc.'s employees to support Pascal's retained intellectual property and scientific programs at no additional cost to Pascal Biosciences Inc., in accordance with a work program to be determined in the definitive agreement. Upon closing of the transaction, Pascal Biosciences Inc. will hold at least 15.8% of the outstanding shares of SORSE Technology. Upon closing of the transaction, SORSE Technology will invest an additional $0.25 million in Pascal Biosciences Inc. on a private placement basis. Pursuant to the term sheet, Pascal Biosciences Inc. has agreed to exclusively negotiate the terms of the transaction with SORSE Technology until May 27, 2020. If entered into, the definitive agreement, and any ancillary transaction agreements, will contain representations and warranties, conditions relating to regulatory approvals, TSX Venture Exchange approvals and any required shareholder approvals, and other terms as are customary in comparable transactions of this nature. In addition, if transaction results in the sale of more than 50% of Pascal Biosciences Inc.’s assets, business or undertaking, as an additional condition to closing of the transaction, Pascal Biosciences Inc. will be required to obtain approval from its shareholders in accordance with Policy 5.3 of the TSX Venture Exchange.
お知らせ • Sep 26Pascal Biosciences Inc. Confirms an Earlier Report Certain Cannabinoids Block Replication of SARS-CoV-2Pascal Biosciences Inc. announced the Company has confirmed an earlier report that certain cannabinoids block replication of SARS-CoV-2, the coronavirus that causes COVID-19. Four different laboratories have now experimentally verified the antiviral activity of a cannabinoid. In addition, several cannabinoids have been tested, and the optimal compound has been chosen for further study. The best cannabinoid had potency similar to remdesivir in two different assays. Remdesivir is an approved drug from Gilead that improves recovery time for COVID-19 patients. The four laboratories testing Pascal compounds are Southern Research, Institut Pasteur Korea, and two independent University of Washington academic groups. Three of the laboratories used the African green monkey kidney epithelial cell line, Vero E6, a common model system for testing coronaviral infectivity. In all three of these assays, the lead cannabinoid had good potency (antiviral activity in the range of 1 to 10 micromolar, similar to remdesivir). The fourth laboratory measured the antiviral effect on SARS-CoV- 2 on the human lung cell line, Calu-3, and found the cannabinoid to be nearly 100-fold more potent in inhibiting virus-mediated cell death than it was in the Vero E6 experiments. This is an important observation, as the human respiratory tract represents the first point of contact with the virus. Pascal scientists are very encouraged by the reproducibility of the cannabinoid's protective activity in different experimental systems and in different laboratories. These results support rationale for testing in animal models of COVID-19, both in single agent and in combination with other antiviral compounds such as remdesivir, and Pascal is currently planning these experiments. There are many efforts to create a vaccine or therapeutic drug for SARS-CoV-2 infection. Pascal's cannabinoid has the potential to limit the severity and progression of the disease. Typically, multiple drugs are required to provide effective antiviral therapy. For example, other viral diseases such as HIV and Hepatitis C require two or three drugs for effective treatment. The novel discovery by Pascal scientists suggests a cannabinoid may well become an essential component of an effective drug cocktail for the treatment of COVID-19. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.
お知らせ • Sep 16Pascal Biosciences Inc. and SoRSE Technology Corporation Enters into a Collaborative Research Agreement to Advance Pascal’s PAS-393 into Clinical TestingPascal Biosciences Inc. and SoRSE Technology Corporation have entered into a Collaborative Research Agreement to advance Pascal’s PAS-393 into clinical testing. Pascal and SoRSE will share their respective technologies to test the cannabinoid PAS-393 in human volunteers, enabling testing of cancer patients treated with checkpoint inhibitors. As initially announced last March, this partnership leverages SoRSE’s formulation technology with Pascal’s proprietary cannabinoid programs for clinical trials. This will be the first pharmaceutical use of the novel formulation technology developed by SoRSE. The agreement will include Pascal’s intellectual property, which covers the use of cannabinoids in cancer patients treated with checkpoint inhibitors. SoRSE currently sells and licenses a proprietary water-soluble cannabinoid emulsion technology (patent-pending) that enables increased bioavailability, accurate dosing, and more than 12 months’ shelf stability. Pascal and SoRSE scientists will optimize a cannabinoid formulation for human subjects and will then test the formulated PAS-393 in volunteers. SoRSE will provide $750,000 in research funding to Pascal throughout the 15-month collaboration and will pay for related research expenditures. Following characterization of safety and pharmacology in a Phase 1a clinical trial, Pascal and SoRSE may elect to continue clinical development as equal partners in a Phase 1b cancer trial in combination with a checkpoint inhibitor. Dr. Gray will present scientific data this September 15th at the 3rd Annual International Cannabinoid-Derived Pharmaceutical Conference occurring in Boston, MA; the topic of his presentation is “Identifying and Validating Mechanism of Action In vivo/vitro.” SoRSE intends to collaborate with other researchers and product developers to study cannabinoids in other medical applications. Pascal will continue to pursue other non-cancer indications for PAS-393.
